FDA Adds Rare Vision Loss Warning to Popular Obesity and Diabetes Drugs
The U.S. Food and Drug Administration announced on November 9, 2026, that popular weight loss drugs like Ozempic and Wegovy will carry a new warning about a rare side effect that can cause permanent vision loss. This warning applies to all GLP-1 drugs, used for obesity, diabetes, and other conditions. The eye condition, non-arteritic anterior ischemic optic neuropathy, results from reduced blood flow to the optic nerve and has been reported across all GLP-1 drugs. FDA analysis found about 6 cases per 100,000 patients after one year of use.
Hindu Health·



